SYGG.F Stock Overview
Synairgen plc discovers and develops drugs for respiratory diseases.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Synairgen plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£0.075 |
| 52 Week High | UK£0.15 |
| 52 Week Low | UK£0.045 |
| Beta | -2.31 |
| 1 Month Change | 34.55% |
| 3 Month Change | 66.84% |
| 1 Year Change | -38.43% |
| 3 Year Change | -95.69% |
| 5 Year Change | n/a |
| Change since IPO | -97.01% |
Recent News & Updates
Recent updates
Shareholder Returns
| SYGG.F | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 13.8% | 2.2% | 1.8% |
| 1Y | -38.4% | 5.8% | 26.1% |
Return vs Industry: SYGG.F underperformed the US Biotechs industry which returned 6.2% over the past year.
Return vs Market: SYGG.F underperformed the US Market which returned 26.3% over the past year.
Price Volatility
| SYGG.F volatility | |
|---|---|
| SYGG.F Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 11.1% |
| Market Average Movement | 5.9% |
| 10% most volatile stocks in US Market | 16.1% |
| 10% least volatile stocks in US Market | 2.8% |
Stable Share Price: SYGG.F's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine SYGG.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2004 | 34 | Richard Marsden | www.synairgen.com |
Synairgen plc discovers and develops drugs for respiratory diseases. It develops SNG001, an inhaled interferon beta for the treatment of COVID-19; inhaled interferon beta (IFN-ß), which is in Phase-II clinical trials for the treatment of asthma caused by the common cold and flu; and IFN-ß that is in Phase-II clinical trials for the treatment or prevention of chronic obstructive pulmonary disease. The company was incorporated in 2004 and is headquartered in Southampton, the United Kingdom.
Synairgen plc Fundamentals Summary
| SYGG.F fundamental statistics | |
|---|---|
| Market cap | US$17.91m |
| Earnings (TTM) | -US$12.69m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-1.4x
P/E RatioIs SYGG.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SYGG.F income statement (TTM) | |
|---|---|
| Revenue | UK£0 |
| Cost of Revenue | UK£0 |
| Gross Profit | UK£0 |
| Other Expenses | UK£9.99m |
| Earnings | -UK£9.99m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.05 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did SYGG.F perform over the long term?
See historical performance and comparison